Generic Name and Formulations:
Mepolizumab 100mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free.
Indications for NUCALA:
As add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.
Limitations Of use:
Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.
Give by SC inj into upper arm, thigh, or abdomen. 100mg once every 4 weeks.
Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Opportunistic infections (eg, herpes zoster); consider varicella vaccination if appropriate prior to starting therapy. Treat pre-existing helminth infections before initiating therapy; discontinue Nucala if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Nucala initiation. Reduction may unmask previously suppressed allergic conditions. Elderly. Pregnancy (monitor closely). Nursing mothers.
Headache, inj site reactions, back pain, fatigue; infections, hypersensitivity reactions; possible antibody formation.